AU2019268412B2 - Peptide activating agent - Google Patents

Peptide activating agent Download PDF

Info

Publication number
AU2019268412B2
AU2019268412B2 AU2019268412A AU2019268412A AU2019268412B2 AU 2019268412 B2 AU2019268412 B2 AU 2019268412B2 AU 2019268412 A AU2019268412 A AU 2019268412A AU 2019268412 A AU2019268412 A AU 2019268412A AU 2019268412 B2 AU2019268412 B2 AU 2019268412B2
Authority
AU
Australia
Prior art keywords
cells
cell
lck
peptide
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019268412A
Other languages
English (en)
Other versions
AU2019268412A1 (en
Inventor
Michael Valentine Agrez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InterK Peptide Therapeutics Ltd
Original Assignee
InterK Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018901673A external-priority patent/AU2018901673A0/en
Application filed by InterK Peptide Therapeutics Ltd filed Critical InterK Peptide Therapeutics Ltd
Publication of AU2019268412A1 publication Critical patent/AU2019268412A1/en
Application granted granted Critical
Publication of AU2019268412B2 publication Critical patent/AU2019268412B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2019268412A 2018-05-15 2019-05-15 Peptide activating agent Active AU2019268412B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901673 2018-05-15
AU2018901673A AU2018901673A0 (en) 2018-05-15 Peptide Activating Agent
PCT/AU2019/050463 WO2019218016A1 (en) 2018-05-15 2019-05-15 Peptide activating agent

Publications (2)

Publication Number Publication Date
AU2019268412A1 AU2019268412A1 (en) 2020-12-03
AU2019268412B2 true AU2019268412B2 (en) 2024-11-07

Family

ID=68539135

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019268412A Active AU2019268412B2 (en) 2018-05-15 2019-05-15 Peptide activating agent

Country Status (8)

Country Link
US (2) US11912789B2 (https=)
EP (1) EP3794014A4 (https=)
JP (1) JP7386852B2 (https=)
KR (1) KR102918269B1 (https=)
CN (1) CN112399970B (https=)
AU (1) AU2019268412B2 (https=)
CA (1) CA3100074A1 (https=)
WO (1) WO2019218016A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518187B (zh) * 2020-04-16 2022-05-10 中国农业科学院饲料研究所 抗菌肽dn6nh2及其应用
JP2024532850A (ja) * 2021-08-20 2024-09-10 インテルク ペプチド セラピューティクス リミテッド がん及びがん療法に関連する自己免疫を含む、自己免疫を処置するための組成物及び方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094085A1 (en) * 2009-02-23 2010-08-26 Inter-K Pty Limited Inhibition of multiple cell activation pathways
US20120277161A1 (en) * 2009-02-23 2012-11-01 Inter-K Pty Limited Inhibition of multiple cell activation pathways
WO2013110120A1 (en) * 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226552B (it) * 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Peptidi immunostimolanti.
AU2005204275B2 (en) * 1999-06-28 2008-10-16 Inter-K Pty Limited A method of modulating integrin mediated cellular activity and agents useful for same
AU2007231835A1 (en) * 2000-12-22 2007-11-29 Inter-K Pty Limited Screening assay for an inhibitor of MAP kinase?integrin binding
JP2007522094A (ja) * 2003-09-22 2007-08-09 アシドフィル エルエルシー 小分子組成物、及びその組成物を使用して薬物効率を高めるための方法
US20050187147A1 (en) 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
WO2009021137A2 (en) 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
CN101854945B (zh) * 2007-09-18 2015-07-01 株式会社绿多肽 Ctl诱导剂组合物
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
EP2378875B1 (en) 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US20110200560A1 (en) * 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
WO2012033911A2 (en) * 2010-09-08 2012-03-15 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
BR112013026199A2 (pt) * 2011-04-15 2017-11-07 Compugen Ltd polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo
US20140186372A1 (en) 2011-06-16 2014-07-03 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
US10954287B2 (en) * 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
CN112368293A (zh) 2018-05-15 2021-02-12 英特肽治疗有限公司 活化剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094085A1 (en) * 2009-02-23 2010-08-26 Inter-K Pty Limited Inhibition of multiple cell activation pathways
US20120277161A1 (en) * 2009-02-23 2012-11-01 Inter-K Pty Limited Inhibition of multiple cell activation pathways
WO2013110120A1 (en) * 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy

Also Published As

Publication number Publication date
AU2019268412A1 (en) 2020-12-03
EP3794014A4 (en) 2022-03-16
CN112399970A (zh) 2021-02-23
JP2021523946A (ja) 2021-09-09
JP7386852B2 (ja) 2023-11-27
WO2019218016A1 (en) 2019-11-21
CN112399970B (zh) 2025-12-12
KR102918269B1 (ko) 2026-01-28
CA3100074A1 (en) 2019-11-21
KR20210021984A (ko) 2021-03-02
EP3794014A1 (en) 2021-03-24
US20210214391A1 (en) 2021-07-15
US11912789B2 (en) 2024-02-27
US20250019397A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
US20260103488A1 (en) Activating agents
US20250019397A1 (en) Peptide Activating Agent
Geng et al. TLR5 ligand–secreting T cells reshape the tumor microenvironment and enhance antitumor activity
US9649339B2 (en) LAT adapter molecule for enhanced T-cell signaling and method of use
AU2017338911B2 (en) HLA-restricted VGLL1 peptides and use thereof
KR20190126798A (ko) 당뇨병 치료를 위한 펩티드 및 방법
US20190262431A1 (en) Cbl-family inhibitor comprising a cbl-family tkb domain binding peptide for the prevention or treatment of diseases
JP2025163127A (ja) 同種異系腫瘍細胞ワクチン
Agrez et al. A novel lipidic peptide with potential to promote balanced effector-regulatory T cell responses
US11702632B2 (en) Ex vivo method of generating super regulatory T cells for the prevention of autoimmune disease
KR20210117217A (ko) 제대혈 혈장 유래의 엑소좀 또는 이의 모방체 및 이의 면역억제 용도
JP2019503696A (ja) 腫瘍浸潤ｔ細胞集団を生成する方法
CN115151274B (zh) Hla限制性hormad1 t细胞受体及其用途
JP2022191303A (ja) Ｆｏｘｐ３結合ペプチド及びその使用
CA3142474A1 (en) A chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy
CA3184316C (fr) Complexe immunomodulateur et ses applications pour la therapie
WO2025247951A1 (en) Fyn kinase inhibitors, combinations and uses thereof
남기리 The roles of T cell-intrinsic CD99 and myeloid cell-expressed IDO1 in T cell response
Kujawa Development of small molecule immunomodulators of the human immune system for cancer therapy
van Loosdregt Post-translational regulation of Foxp3: identification of novel molecular targets for immune modulation
Schoufour No el insights into MHC-I function using CRISPR/Cas9 screens

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)